NCT02151110View on ClinicalTrials.gov

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

May 27, 2014

Primary Completion Date

May 9, 2016

Study Completion Date

May 9, 2016

Conditions
Healthy Volunteer
Interventions
BIOLOGICAL

MEDI4920 3 mg

Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.

BIOLOGICAL

MEDI4920 10 mg

Participants received single IV dose of MEDI4920 10 mg infused on Day 1.

BIOLOGICAL

MEDI4920 30 mg

Participants received single IV dose of MEDI4920 30 mg infused on Day 1.

BIOLOGICAL

MEDI4920 100 mg

Participants received single IV dose of MEDI4920 100 mg infused on Day 1.

BIOLOGICAL

MEDI4920 300 mg

Participants received single IV dose of MEDI4920 300 mg infused on Day 1.

BIOLOGICAL

MEDI4920 1000 mg

Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.

BIOLOGICAL

MEDI4920 3000 mg

Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.

OTHER

Placebo

Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.

Trial Locations (1)

LS2 9LH

Research Site, Leeds

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY